Adding nivolumab to neoadjuvant chemo improves response rate for high risk ER+ HER2− breast cancer

Share :
Published: 22 Oct 2023
Views: 39
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Sherene Loi speaks to ecancer about the CheckMate 7FL study which explored nivolumab or placebo in combination with neoadjuvant chemotherapy, followed by adjuvant endocrine therapy in patients with high-risk estrogen receptor positive, HER2-negative primary breast cancer.

She discusses the main objective was to evaluate nivolumab in this setting in combination of neoadjuvant chemotherapy.

The study met its primary endpoint with significantly improved pathological complete response and residual cancer burden 0–1 rates (enhanced in PD-L1 positive patients) with nivolumab plus neoadjuvant chemotherapy, with increased immune-related adverse events.

  • Categories: